Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients

Giuseppe Di Lorenzo, Giacomo Cartenì, Riccardo Autorino, Antonio Gonnella, Sisto Perdonà, Matteo Ferro, Nicola Longo, Pasquale Rescigno, Francesca Doria, Adriana Faiella, Vincenzo Altieri, Giovannelia Palmieri, Ciro Imbimbo, Vincenzo Mirone, Sabino De Placido

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The objective of this study was to evaluate the use of paclitaxel in patients with advanced squamous cell penile cancer previously treated with neoadjuvant cisplatin-based chemotherapy. This was a single-arm, phase II, multicenter study. Patients were treated with 175mg/m2 paclitaxel at a 3-week interval, until disease progression or irreversible toxicity. The primary end point was the objective response rate. Secondary end points were safety, progression-free survival, and overall survival. Twelve patients were enrolled. Partial responses were observed in 25% (3 of 12) of patients (95% confidence interval: 12-40%). Grade 3 neutropenia and oral mucositis were the most common side effects, each noted in three patients. Median progression-free survival was 4 months (range 2-6 months) and median overall survival was 6 months (range 3-10 months). Paclitaxel is well tolerated and associated with promising efficacy. Further trials, also in a neoadjuvant setting, are needed to corroborate our preliminary findings.

Original languageEnglish
Pages (from-to)277-280
Number of pages4
JournalAnti-Cancer Drugs
Volume20
Issue number4
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Penile Neoplasms
Paclitaxel
Disease-Free Survival
Squamous Cell Neoplasms
Stomatitis
Survival
Neutropenia
Cisplatin
Multicenter Studies
Disease Progression
Confidence Intervals
Safety
Drug Therapy

Keywords

  • Activity and toxicity
  • Metastatic penile cancer
  • Paclrtaxel

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. / Lorenzo, Giuseppe Di; Cartenì, Giacomo; Autorino, Riccardo; Gonnella, Antonio; Perdonà, Sisto; Ferro, Matteo; Longo, Nicola; Rescigno, Pasquale; Doria, Francesca; Faiella, Adriana; Altieri, Vincenzo; Palmieri, Giovannelia; Imbimbo, Ciro; Mirone, Vincenzo; De Placido, Sabino.

In: Anti-Cancer Drugs, Vol. 20, No. 4, 04.2009, p. 277-280.

Research output: Contribution to journalArticle

Lorenzo, GD, Cartenì, G, Autorino, R, Gonnella, A, Perdonà, S, Ferro, M, Longo, N, Rescigno, P, Doria, F, Faiella, A, Altieri, V, Palmieri, G, Imbimbo, C, Mirone, V & De Placido, S 2009, 'Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients', Anti-Cancer Drugs, vol. 20, no. 4, pp. 277-280. https://doi.org/10.1097/CAD.0b013e328329a293
Lorenzo, Giuseppe Di ; Cartenì, Giacomo ; Autorino, Riccardo ; Gonnella, Antonio ; Perdonà, Sisto ; Ferro, Matteo ; Longo, Nicola ; Rescigno, Pasquale ; Doria, Francesca ; Faiella, Adriana ; Altieri, Vincenzo ; Palmieri, Giovannelia ; Imbimbo, Ciro ; Mirone, Vincenzo ; De Placido, Sabino. / Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. In: Anti-Cancer Drugs. 2009 ; Vol. 20, No. 4. pp. 277-280.
@article{c30498811463449283f56152c89a7829,
title = "Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients",
abstract = "The objective of this study was to evaluate the use of paclitaxel in patients with advanced squamous cell penile cancer previously treated with neoadjuvant cisplatin-based chemotherapy. This was a single-arm, phase II, multicenter study. Patients were treated with 175mg/m2 paclitaxel at a 3-week interval, until disease progression or irreversible toxicity. The primary end point was the objective response rate. Secondary end points were safety, progression-free survival, and overall survival. Twelve patients were enrolled. Partial responses were observed in 25{\%} (3 of 12) of patients (95{\%} confidence interval: 12-40{\%}). Grade 3 neutropenia and oral mucositis were the most common side effects, each noted in three patients. Median progression-free survival was 4 months (range 2-6 months) and median overall survival was 6 months (range 3-10 months). Paclitaxel is well tolerated and associated with promising efficacy. Further trials, also in a neoadjuvant setting, are needed to corroborate our preliminary findings.",
keywords = "Activity and toxicity, Metastatic penile cancer, Paclrtaxel",
author = "Lorenzo, {Giuseppe Di} and Giacomo Carten{\`i} and Riccardo Autorino and Antonio Gonnella and Sisto Perdon{\`a} and Matteo Ferro and Nicola Longo and Pasquale Rescigno and Francesca Doria and Adriana Faiella and Vincenzo Altieri and Giovannelia Palmieri and Ciro Imbimbo and Vincenzo Mirone and {De Placido}, Sabino",
year = "2009",
month = "4",
doi = "10.1097/CAD.0b013e328329a293",
language = "English",
volume = "20",
pages = "277--280",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients

AU - Lorenzo, Giuseppe Di

AU - Cartenì, Giacomo

AU - Autorino, Riccardo

AU - Gonnella, Antonio

AU - Perdonà, Sisto

AU - Ferro, Matteo

AU - Longo, Nicola

AU - Rescigno, Pasquale

AU - Doria, Francesca

AU - Faiella, Adriana

AU - Altieri, Vincenzo

AU - Palmieri, Giovannelia

AU - Imbimbo, Ciro

AU - Mirone, Vincenzo

AU - De Placido, Sabino

PY - 2009/4

Y1 - 2009/4

N2 - The objective of this study was to evaluate the use of paclitaxel in patients with advanced squamous cell penile cancer previously treated with neoadjuvant cisplatin-based chemotherapy. This was a single-arm, phase II, multicenter study. Patients were treated with 175mg/m2 paclitaxel at a 3-week interval, until disease progression or irreversible toxicity. The primary end point was the objective response rate. Secondary end points were safety, progression-free survival, and overall survival. Twelve patients were enrolled. Partial responses were observed in 25% (3 of 12) of patients (95% confidence interval: 12-40%). Grade 3 neutropenia and oral mucositis were the most common side effects, each noted in three patients. Median progression-free survival was 4 months (range 2-6 months) and median overall survival was 6 months (range 3-10 months). Paclitaxel is well tolerated and associated with promising efficacy. Further trials, also in a neoadjuvant setting, are needed to corroborate our preliminary findings.

AB - The objective of this study was to evaluate the use of paclitaxel in patients with advanced squamous cell penile cancer previously treated with neoadjuvant cisplatin-based chemotherapy. This was a single-arm, phase II, multicenter study. Patients were treated with 175mg/m2 paclitaxel at a 3-week interval, until disease progression or irreversible toxicity. The primary end point was the objective response rate. Secondary end points were safety, progression-free survival, and overall survival. Twelve patients were enrolled. Partial responses were observed in 25% (3 of 12) of patients (95% confidence interval: 12-40%). Grade 3 neutropenia and oral mucositis were the most common side effects, each noted in three patients. Median progression-free survival was 4 months (range 2-6 months) and median overall survival was 6 months (range 3-10 months). Paclitaxel is well tolerated and associated with promising efficacy. Further trials, also in a neoadjuvant setting, are needed to corroborate our preliminary findings.

KW - Activity and toxicity

KW - Metastatic penile cancer

KW - Paclrtaxel

UR - http://www.scopus.com/inward/record.url?scp=63449096646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449096646&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e328329a293

DO - 10.1097/CAD.0b013e328329a293

M3 - Article

C2 - 19262371

AN - SCOPUS:63449096646

VL - 20

SP - 277

EP - 280

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 4

ER -